NEW YORK (GenomeWeb) – Natera and the Feinstein Institute for Medical Research will partner to conduct research on cell-free circulating tumor DNA in order to detect, diagnose, and monitor cancer.

Natera will provide funding to the Feinstein Institute, which will contribute blood and tissue samples. Natera will develop technology for detecting ctDNA.

"Our vision is to enable cancer detection across multiple tumor types that will have the same key features as our prenatal tests: early, accurate, and non-invasive," said Natera CEO Matthew Rabinowitz in a statement.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Helix customers can purchase apps that interpret different aspects of their genome, Technology Review reports.

The New York Times reports that a number of companies and research institutes are pursuing gene therapies.

Salmon with shorter telomeres survive to make the trip back to their river homes, New Scientist reports.

In PLOS this week: vaginal microbiome composition, population patterns of Chagas-carrying Rhodnius ecuadoriensis, and more.